Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2021-11-02 00:00:00 ET · period of report 2021-11-01 · accession 0001725160-21-000210 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-02 | 2021-11-01 | ZNTL | Blackwell Kimberly | Dir | M - OptEx | $47.80 | +1,000 | 6,000 | +20% | +$47.8K |
| D | 2021-11-02 | 2021-11-01 | ZNTL | Blackwell Kimberly | Dir | S - Sale+OE | $80.46 | -1,000 | 5,000 | -17% | -$80.5K |
| D | 2021-11-02 | 2021-11-01 | ZNTL | Blackwell Kimberly | Dir | M - OptEx | $0.00 | -1,000 | 40.0K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-01 | M | A | 1,000 | $47.80 | 6,000 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-01 | S | D | 1,000 | $80.46 | 5,000 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2021-11-01 | M | D | 1,000 | $0.00 | 40,000 | D | $47.80 · — to 2030-06-30 | 1,000 Common Stock | (F2) The options vest and become exercisable in substantially equal monthly installments over the 36 months following the date of grant, July 1, 2020. |